TrialNature communications2022

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.

R C Coombes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.